Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.49 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | NPEPPS | P55786 | 6/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.46 |
| ▸ | ANPEP | P15144 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.44 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18512597 | 1.00 | LMNA (0.62) | LMNAP2RX3P2RX4P2RX2ADORA2A | |
| SCHEMBL17032321 | 0.93 | LMNA (0.62) | LMNAP2RX3P2RX4P2RX2ADORA2A | |
| SCHEMBL29672348 | 0.92 | LMNA (0.64) | LMNAP2RX3P2RX4P2RX2ADORA2A | |
| SCHEMBL17677178 | 0.92 | LMNA (0.64) | LMNAP2RX3P2RX4P2RX2ADORA2A | |
| SCHEMBL29672354 | 0.92 | LMNA (0.64) | LMNAP2RX3P2RX4P2RX2ADORA2A | |
| SCHEMBL13084426 | 0.87 | LMNA (0.59) | LMNAP2RX3P2RX4P2RX2ADORA2A | |
| SCHEMBL18512579 | 0.86 | LMNA (0.55) | LMNAP2RX3P2RX4P2RX2ADORA2A | |
| SCHEMBL13863569 | 0.85 | LMNA (0.75) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL13046095 | 0.85 | LMNA (0.75) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL13084357 | 0.85 | LMNA (0.75) | LMNAP2RX3P2RX4P2RX2ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181294-B2 | Nucleoside analogues for the treatment of a viral infection, and method for evaluating the sensitivity to said treatment | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2015-11-10 | — | — | US | disclosed |
| US-20140323425-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323425-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT | SAMHD1, NUDT1, TYMP | LMNA 1458/4885P2RX3 1111/4885P2RX4 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.